Trials / Completed
CompletedNCT02805205
PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy to Prevent Neutropenia
A Multi-center, Open-label,Single Arm Phase IV Clinical Trial of Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia in Patients With Breast Cancer Receiving Chemotherapy
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 484 (actual)
- Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to estimate the efficacy and safety of PEG-rhG-CSF in patients with breast cancer receiving chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PEG-rhG-CSF |
Timeline
- Start date
- 2013-04-01
- Primary completion
- 2016-02-01
- Completion
- 2016-02-01
- First posted
- 2016-06-17
- Last updated
- 2016-06-20
Source: ClinicalTrials.gov record NCT02805205. Inclusion in this directory is not an endorsement.